Abbreviations used in this paper: Foxo, forkhead box gene, group O; IGF, insulin-like growth factor; MyHC, myosin heavy chain; PI 3-kinase, phosphatidylinositol 3-kinase; RD, rhabdomyosarcoma-derived.

Introduction
============

Muscle development is a multi-step process that begins with the determination of myogenic precursors from mesodermal stem cells and concludes with differentiation of committed myoblasts ([@bib23]). This program depends on myogenic effectors of the MyoD family ([@bib37]) and their cooperation with myocyte-specific enhancer-binding factors, such as MEF2 ([@bib23]). These proteins activate expression of genes required for muscle differentiation through heterodimer formation with other ubiquitous bHLH proteins and by binding to E boxes, cis-acting elements found in the promoter regions of muscle-restricted genes ([@bib30]).

Most peptide growth factors stimulate myoblast proliferation and prevent differentiation ([@bib8]). In contrast, insulin-like growth factors (IGFs) promote myoblast differentiation in vitro ([@bib8]; [@bib35]). In cultured myoblasts, autocrine production of IGF2 is associated with differentiation triggered by serum withdrawal ([@bib32]; [@bib33]; [@bib18]). Inactivation of IGF signaling by targeted mutagenesis of the gene-encoding IGF1 receptor leads to muscle hypoplasia ([@bib22]), whereas IGF1 overexpression in muscle results in enlarged myofibers ([@bib6]), suggesting that IGFs participate in myogenesis in vivo.

IGF signaling activates the phosphatidylinositol 3-kinase (PI 3-kinase) and the MAPK pathways ([@bib15]). Although several reports indicate a requirement for PI 3-kinase activity in the activation of myogenic program ([@bib11]; [@bib14]), the MAPK pathway does not appear to contribute to IGF-dependent myogenesis ([@bib8]; [@bib20]; [@bib35]; [@bib7]). Among the effectors of PI 3-kinase, the serine/threonine kinase Akt has been shown to induce transcription of muscle-specific genes ([@bib12]), thus resulting in myoblast differentiation ([@bib20]; [@bib19]). However, Akt substrates required for completion of the myogenic process are unknown. Some evidence indicates that p70^s6k1^ participates in myogenesis ([@bib9]), whereas the role of mTOR is unclear. Analyses with the mTOR inhibitor rapamycin have yielded conflicting results, with some suggesting that rapamycin inhibits ([@bib8]; [@bib9]; [@bib7]) and others suggesting that rapamycin promotes myoblast differentiation ([@bib10]). Notably, other authors have reported no effect of rapamycin in this process ([@bib5]).

Forkhead transcription factors of the forkhead box gene, group O (Foxo) subfamily ([@bib13]) are phosphorylated in an insulin-responsive manner by Akt and Sgk ([@bib3], [@bib4]; [@bib25]). Phosphorylation leads to Foxo inhibition through nuclear exclusion. Foxo proteins mediate several transcriptional effects of insulin and IGFs, including those on hepatic glucose production ([@bib27], [@bib28]), pancreatic β-cell proliferation ([@bib16]), and adipocyte differentiation ([@bib29]). To study the role of Foxo proteins in myoblast differentiation, we examined the effects of constitutively active and dominant-negative mutant Foxo1 on in vitro differentiation of cultured myoblasts, teratocarcinoma cells, and rhabdomyosarcoma cells. To examine pathways impinging on Foxo1 regulation of myogenesis, we also studied the ability of Foxo1 mutants to regulate myoblast differentiation in the presence of pharmacological inhibitors of the PI 3-kinase and mTOR pathways, as well as constitutively active Akt. Our data identify Foxo proteins as key effectors of Akt-dependent myogenesis.

Results and discussion
======================

Expression and phosphorylation of Foxo isoforms during differentiation
----------------------------------------------------------------------

C~2~C~12~ cells undergo growth arrest and induction of the myogenic program after incubation in serum-free medium.

There are three Foxo isoforms in mice: Foxo1, -3 and -4 ([@bib13]). *Foxo4* and *Foxo1* are the most abundant transcripts in skeletal muscle ([@bib16]). Using Western analysis, we measured expression of the three proteins in myoblasts and myotubes. The relative abundance of all three isoforms declined in myotubes compared with myoblasts, but the difference was not statistically significant ([Fig. 1](#fig1){ref-type="fig"} A). Next, we used phospho-specific antibodies to measure phosphate content of the main phosphorylation site (S253 in Foxo1, S193 in Foxo4). In myotubes, phosphate content increased by 38 and 40% for Foxo1 and Foxo4, respectively. To measure Foxo3 phosphorylation, we used an electrophoretic gel shift assay. We detected an 85% increase in the amount of low mobility (phosphorylated) protein in myotubes ([Fig. 1](#fig1){ref-type="fig"} B). These data indicate that differentiation is associated with increased Foxo phosphorylation. From these observations, it can be inferred that myogenic differentiation requires Foxo1 inhibition, similar to what has been observed in adipocytes ([@bib29]) and thymocytes ([@bib21]).

![**Foxo isoform expression and phosphorylation levels in C** ~2~ **C~12~ myoblasts and myotubes.** (A) Extracts of C~2~C~12~ myoblasts and myotubes were immunoblotted with the antisera indicated on the right side. (B) Levels of phosphorylated Foxo1 and Foxo4 were assessed by immunoblotting with phospho-specific antisera (S253 for Foxo1, S193 for Foxo4), whereas electrophoretic gel mobility shift was used as a surrogate measure of Foxo3 phosphorylation. The phosphorylated protein migrates more slowly on SDS-PAGE. Mean ± SEM of densitometric scanning values was calculated from three independent experiments. Immunoblotting with anti-cyclophilin antiserum was used as a control for gel loading (not depicted). Asterisk indicates P \< 0.01.](200212107f1){#fig1}

Foxo1 mutants modulate myoblast differentiation
-----------------------------------------------

Because Akt mediates IGF-dependent C~2~C~12~ differentiation ([@bib19]; [@bib35]) and Foxo isoforms are Akt substrates ([@bib3]), we investigated whether they mediate myoblast differentiation. We used adenovirus-mediated gene transfer to express constitutively active (ADA) and dominant-negative (Δ256) Foxo1 mutants in myoblasts. The constitutively active mutant cannot be phosphorylated and fails to translocate in response to insulin, whereas the dominant-negative mutant lacks the transactivation domain ([@bib25]). The Δ256-Foxo1 or ADA-Foxo1 adenoviruses were expressed at high levels after transduction ([Fig. 2](#fig2){ref-type="fig"} A, lane 2 and lane 3). After 96 h in differentiation medium, cells transduced with the ADA mutant failed to convert to myotubes, whereas cells transduced with the Δ256 mutant were morphologically indistinguishable from control cells ([Fig. 2](#fig2){ref-type="fig"} B). Accordingly, the ADA mutant prevented expression of myosin heavy chain (MyHC), a marker of terminally differentiated myotubes. Conversely, transduction with Δ256 caused a 30% increase in MyHC expression ([Fig. 2, B and C](#fig2){ref-type="fig"}).

###### 

**Expression of early and late differentiation markers in C** ~2~ **C~12~ transduced with Foxo1 mutants.** (A) Expression of Foxo1 mutants following adenovirus-mediated gene transfer. Extracts from control cells (lane 1) or from cells transduced with D256-Foxo1 (lane 2) or ADA-Foxo1 (lane 3) were analyzed by immunoblotting with anti-Foxo1 antiserum. (B) Detection of myosin expression by immunocytochemistry. (C) Immunoblot analysis of MyHC expression in cells expressing ADA-Foxo1 or Δ256-Foxo1. A representative blot is shown at the top, and a graph summarizing several experiments is shown on the bottom. The same filter was stripped and reprobed with anti-cyclophilin antiserum (Cy) to normalize protein content (bottom). Asterisk indicates P \< 0.01. (D) Myogenin expression in cells expressing mutant Foxo1. Extracts were obtained from untransduced cells (lanes 1--3), cells expressing Δ256-Foxo1 (lanes 4--6), and ADA-Foxo1 (lanes 7--9) at the indicated time points and analyzed by SDS-PAGE, followed by immunoblot with anti-myogenin (top) or anti-cyclophilin antiserum (bottom). Data from three separate experiments are summarized in the bar graphs at the bottom. Scanning densitometry of the autoradiograms was used to measure MyHC and myogenin expression. Data are plotted as mean ± SEM. An asterisk indicates P \< 0.01. (E) Phosphorylation of Gsk3 in cells transduced with ADA-Foxo1. Lysates were analyzed by Western blotting with a phosphoSer^9--21^-specific Gsk3 antiserum (top) and a total Gsk3 antiserum (bottom).
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Myogenin is an early differentiation marker. In myoblasts, its expression was induced between 4 and 8 h of serum withdrawal. The transient decrease in myogenin expression during differentiation has been observed by others ([@bib17]), and does not appear to interfere with the cells\' ability to undergo complete differentiation into myotubes ([Fig. 2](#fig2){ref-type="fig"} B). Cells transduced with Δ256 showed a 70% increase of myogenin levels compared with untransduced cells. In contrast, ADA-transduced cells showed a 20% decrease ([Fig. 2](#fig2){ref-type="fig"} D). These data are consistent with the observation that the Foxo1 gain-of-function mutant impairs differentiation, whereas the dominant-negative Foxo1 increases the efficiency of differentiation.

The effect of the ADA mutant could not be accounted for by nonspecific inhibition of Akt function because phosphorylation of Gsk3, another Akt substrate, was unaffected in cells expressing the ADA-Foxo1 mutant ([Fig. 2](#fig2){ref-type="fig"} E).

We obtained additional evidence that Foxo inhibition is required for differentiation using siRNA to decrease Foxo mRNA levels. We designed two siRNAs, one directed against a Foxo1-specific sequence, and one against a pan-Foxo--specific sequence. Transfection of the pan-Foxo siRNA resulted in 70--90% decreases in mRNA levels encoding all three isoforms ([Fig. 3](#fig3){ref-type="fig"} A), and was accompanied by a 30% increase in MyHC expression ([Fig. 3](#fig3){ref-type="fig"} C). In contrast, transfection of the Foxo1-specific siRNA inhibited expression of Foxo1 ([Fig. 3](#fig3){ref-type="fig"} B), but not of Foxo3 and -4, and induced a lesser increase in MyHC expression ([Fig. 3](#fig3){ref-type="fig"} C).

![**siRNA-mediated inhibition of Foxo expression.** Expression of mRNA encoding the three Foxo isoforms in cells transfected with increasing concentrations of pan-Foxo (A) or Foxo1-specific siRNA (B). Results are expressed as a percentage of control. (C) Immunoblot analysis of MyHC expression in cells transfected with pan-Foxo (light gray), Foxo1-specific siRNA (dark gray), or control siRNA (black, top). The same filter was stripped and reprobed with anti-cyclophilin antiserum (Cy) to normalize protein content (bottom).](200212107f3){#fig3}

Δ256 Foxo1 partly rescues wortmannin inhibition of myoblast differentiation
---------------------------------------------------------------------------

Inhibition of PI 3-kinase prevents myoblast differentiation ([@bib11]; [@bib35]). Because Foxo proteins are regulated by PI 3 kinase--dependent and --independent pathways ([@bib4]; [@bib26]), we evaluated the ability of Δ256 to rescue inhibition of myogenesis by wortmannin. Treatment with wortmannin inhibited differentiation and prevented MyHC expression. Transduction with Δ256 restored MyHC expression to ∼50% of control levels and was associated with partial restoration of the myotube phenotype ([Fig. 4](#fig4){ref-type="fig"} A). These data indicate that Foxo1 mediates some of the effects of PI 3-kinase on differentiation. However, the failure of Δ256 to completely reverse the effect of wortmannin is consistent with the presence of Foxo-independent mechanisms of myogenesis downstream of PI 3-kinase.

![**Signaling pathways involved in Foxo1 regulation of myoblast differentiation.** (A) Δ256-Foxo1 partly rescues wortmannin inhibition of myoblast differentiation. C, control cells; W, wortmannin-treated cells; Δ, cells expressing Δ256-Foxo1; Δ + W, Δ 256-expressing cells that have been treated with wortmannin. Extracts were obtained 96 h after the induction of differentiation. The bar graph summarizes the results of three experiments. (B) ADA-Foxo1 overrides the effect of Myr-Akt to stimulate myoblast differentiation. Extracts from control cells (C) and cells transduced with Myr-Akt (Myr), ADA-Foxo1 (ADA), or both (Myr + ADA) were prepared 96 h after the induction of differentiation. Equal amounts of protein were subjected to SDS-PAGE and were immunoblotted with anti-MyHC (top) or anti-cyclophilin antiserum (bottom). (C) Δ256-Foxo1 fails to override the inhibitory effect of rapamycin on C~2~C~12~ differentiation. Immunoblot analyses with anti-MyHC (top) and anti-cyclophilin (bottom) antisera were performed on extracts obtained from control (C), rapamycin-treated (R), and Δ256-expressing cells (Δ + R) as indicated above. (D) Δ256-Foxo1 induces myogenic conversion of P19 teratocarcinoma cells independently of DMSO treatment. P19 cells were differentiated in the presence (lane 1 and lane 4) or absence (lane 2 and lane 3) of DMSO and were transduced with either Δ256-Foxo1 (lane 2) or ADA-Foxo1 (lane 4). Lane 5 and lane 6 show control RD cells and RD transduced with Δ256-Foxo1. The bar graphs represent mean ± SEM densitometric values from three or four experiments for each condition. One asterisk indicates P \< 0.01 in A--C, and P \< 0.005 in D. Cyclophilin was used to normalize gel loading.](200212107f4){#fig4}

ADA Foxo1 prevents differentiation induced by Myr-Akt
-----------------------------------------------------

Akt stimulates myoblast differentiation ([@bib8]; [@bib19]). Transduction with a constitutively active Myr-Akt promoted differentiation and increased MyHC expression twofold. However, cotransduction of Myr-Akt and ADA-Foxo1 prevented differentiation induced by Myr-Akt and decreased MyHC expression to the same levels seen in cells transduced with ADA-Foxo1 alone ([Fig. 4](#fig4){ref-type="fig"} B). These data suggest that Akt-induced myogenesis is mediated by Foxo.

Δ256-Foxo1 fails to reverse rapamycin inhibition of differentiation
-------------------------------------------------------------------

Among the PI 3-kinase effectors, some authors have shown that p70^s6k^ is required for differentiation ([@bib8]; [@bib9]; [@bib7]). Inhibition of mTOR by rapamycin resulted in an approximate 70% decrease of MyHC levels and blocked myogenic differentiation. The inhibition of MyHC expression by rapamycin was unaffected by Δ256-Foxo1 ([Fig. 4](#fig4){ref-type="fig"} C; P \< 0.001), suggesting that the mTOR pathway does not act through Foxo to promote differentiation.

Δ256-Foxo1 induces differentiation of teratocarcinoma, but not of rhabdomyosarcoma cells
----------------------------------------------------------------------------------------

P19 teratocarcinoma cells are able to undergo myogenic conversion when cultured with DMSO. When P19 cells were transduced with the Δ256-Foxo1, differentiation occurred in the absence of DMSO, and MyHC expression increased to levels similar to DMSO-treated cells ([Fig. 4](#fig4){ref-type="fig"} D, lanes 1--4 and bar graph). In contrast, transduction with the ADA mutant inhibited DMSO-induced differentiation and reduced MyHC expression by ∼70%. Thus, a loss-of-function Foxo1 mutation enhances myoblast differentiation of P19 cells, whereas a gain-of-function mutation impairs it.

Rhabdomyosarcoma-derived (RD) cells lack functional IGF signaling ([@bib24]). Most rhabdomyosarcomas carry chromosomal translocations in which the DNA-binding domain of Foxo1 is fused to the transactivation domain of Pax3 or Pax8 ([@bib36]; [@bib24]). We tested whether Foxo1 inhibition would restore differentiation by transducing cells with Δ256-Foxo1 and by culturing them in differentiation medium. However, we failed to detect morphological changes or increases in MyHC expression ([Fig. 3](#fig3){ref-type="fig"} D, lane 5 and lane 6). Thus, Foxo1 inhibition alone cannot rescue the transformed phenotype of RD cells.

Conclusions
-----------

Our data provide evidence for a key role of Foxo transcription factors as mediators of IGF-dependent myoblast differentiation. We provide two lines of evidence to support our conclusions. Foxo1 gain-of-function is associated with impaired myoblast differentiation, whereas loss-of-function is able to partly restore inhibition of differentiation by wortmannin. Furthermore, constitutively active Foxo1 inhibited, whereas dominant-negative mutant Foxo1 caused a slight, but significant increase in the expression of differentiation markers. Consistent with the notion that Foxo is regulated by Akt, we also found that the ability of constitutively active Akt to induce differentiation ([@bib31]) can be blocked by the phosphorylation-defective Foxo1 mutant. These data identify Foxo1 as a key component of the Akt pathway in differentiation. This pathway requires activation of the cell cycle inhibitor p21 ([@bib19]), a Foxo1 target in differentiating adipocytes ([@bib29]). Although we have not examined p21 expression in C~2~C~12~, it is likely to be an important Foxo target in myoblasts as well.

The inability of the dominant-negative Foxo1 to completely reverse the inhibition of differentiation caused by wortmannin suggests that multiple effectors of differentiation act downstream of PI 3-kinase. Similarly, the dominant-negative Foxo1 failed to reverse rapamycin inhibition of myoblast differentiation, indicating that Foxo1 phosphorylation by mTOR is not required for this process. We suggest that signals regulating myoblast differentiation diverge downstream of PI 3-kinase, with both Akt and mTOR playing a role in the process.

Foxo1 inhibition restored myogenic differentiation of teratocarcinoma-derived cells, but not of rhabdomyosarcoma-derived cells. RD cells express myogenic factors, such as MyoD and myogenin, but these factors are transcriptionally inactive ([@bib34]). It has also been shown that RDs are defective in their PI 3-kinase→Akt signaling ([@bib39]), and that constitutively active forms of PI 3-kinase and Akt fail to restore differentiation. Now, we extend those data by showing that inhibition of Foxo1 function is equally unable to restore the differentiated phenotype, suggesting that the defect in RD cells is distal to Foxo1.

After the submission of this manuscript, it has been reported that Foxo1 promotes differentiation of primary myoblasts ([@bib2]). These conclusions are at odds with our data, and appear to be due to substantial differences in the experimental system, such as the dissociation of Foxo1 phosphorylation from nuclear localization, the lack of Akt regulation of Foxo1, and the failure of dominant-negative Akt to affect differentiation.

In conclusion, we show that Foxo1 plays in important role in regulating skeletal muscle differentiation through the PI3K→Akt pathway. Further work will identify Foxo1 targets involved in this process.

Materials and methods
=====================

Reagents
--------

We obtained C~2~C~12~, P19, and RD cells from the American Type Culture Collection, anti- Foxo1 antibodies from Santa Cruz Biotechnology, Inc., anti-HA antibody 12CA5 from Boehringer, anti-MyHC (clone MF 20) and anti-myogenin antibodies (clone F5D) from the Hybridoma Bank (University of Iowa, Iowa City, IA), and anti phospho-Gsk3 and anti-Gsk3 antisera from Upstate Biotechnology. C~2~C~12~, P19 ([@bib38]), and RD cells ([@bib24]) were maintained and differentiated as described previously ([@bib1]). Foxo1 and Akt adenoviral vectors have been described previously ([@bib27]). Western blotting was performed according to standard procedures.

Design and transfection of siRNAs
---------------------------------

We used the target finder and design tool (Ambion) to identify target siRNAs. The Foxo1-specific sequence was 5′-AAAAGTCCTTCAGATTGTCTG-3′. The pan-Foxo sequence was 5′-AAGGATAAGGGCGACAGACC-3′. SiRNA synthesis and transfection with siPORT™ reagents was performed according to the manufacturer\'s instructions (Ambion). Foxo expression was measured by real-time RT-PCR using a LightCycler PCR instrument (Roche) and LightCycler SYBR^®^ Green I reaction mix (Roche). Each reaction was performed in triplicate under standard reaction conditions. β-Actin was used as a control of amplification efficiency.

Immunofluorescence
------------------

Cells were cultured on microscope slides, differentiated, and fixed in 4% PFA. After incubation with anti-MyHC IgG2b at 1:500, detection was performed using DAPC-conjugated secondary antibody ([@bib29]).

Statistical analysis
--------------------

Statistical analysis was performed using *t* test for paired data.
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